We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
- Authors
Qiu-Yan Chen; Shao-Yan Guo; Lin-Quan Tang; Tong-Yu Lu; Bo-Lin Chen; Qi-Yu Zhong; Meng-Sha Zou; Qing-Nan Tang; Wen-Hui Chen; Shan-Shan Guo; Li-Ting Liu; Yang Li; Ling Guo; Hao-Yuan Mo; Rui Sun; Dong-Hua Luo; Chong Zhao; Ka-Jia Cao; Chao-Nan Qian; Xiang Guo
- Abstract
Purpose Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors. Materials and Methods By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above. Results Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm³; EBV DNA 0 copy/mL, GTVtotal 30 cm³; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm³) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal ≥ 30 cm³). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant. Conclusion Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.
- Subjects
EPSTEIN-Barr virus; INTENSITY modulated radiotherapy; BIOMARKERS; METASTASIS
- Publication
Cancer Research & Treatment, 2018, Vol 50, Issue 3, p861
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2017.237